RSV and HMPV vaccine study for adults 60 and older
Part of Infections, Lungs & breathing clinical trials.
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You cannot become pregnant (for women, this means at least one year past menopause or surgically sterile).
- You have not had a lab-confirmed RSV or HMPV infection in the last 12 months, and no one in your house has had one either.
- You have never had a heart muscle or heart lining inflammation condition (myocarditis, pericarditis, or myopericarditis).
- You have not received any other RSV or HMPV vaccine before, and no mRNA vaccine in the last 2 months.
- You have not had Guillain-Barré Syndrome or a blood transfusion in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that protects against two common respiratory viruses: RSV and HMPV. It aims to see if the vaccine is safe and works well in older adults, who are at higher risk for serious illness from these viruses.
This study tests a new vaccine that may protect against two common viruses that cause breathing problems, RSV and hMPV. It is for healthy younger adults (18-49) and older adults (60-80) to see if the vaccine is safe and works well.
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Hear when a new Respiratory Syncytial Virus Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.